KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Thermo Fisher Scientific (TMO) Equity Average (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of Equity Average readings, the most recent being $52.7 billion for Q1 2026.

  • On a quarterly basis, Equity Average rose 6.51% to $52.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $52.7 billion, a 6.51% increase, with the full-year FY2025 number at $51.5 billion, up 6.95% from a year prior.
  • Equity Average hit $52.7 billion in Q1 2026 for Thermo Fisher Scientific, up from $52.2 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $52.7 billion in Q1 2026 to a low of $40.9 billion in Q2 2022.
  • Median Equity Average over the past 5 years was $46.1 billion (2024), compared with a mean of $46.5 billion.
  • Biggest five-year swings in Equity Average: rose 17.66% in 2022 and later grew 3.29% in 2023.
  • Thermo Fisher Scientific's Equity Average stood at $43.8 billion in 2022, then increased by 5.05% to $46.0 billion in 2023, then rose by 7.01% to $49.3 billion in 2024, then rose by 6.0% to $52.2 billion in 2025, then grew by 0.87% to $52.7 billion in 2026.
  • The last three reported values for Equity Average were $52.7 billion (Q1 2026), $52.2 billion (Q4 2025), and $50.8 billion (Q3 2025) per Business Quant data.